Latest Philadelphia chromosome Stories
- Fewer patients on Tasigna vs. Gleevec had their leukemia progress to advanced stage, a key goal of treatment in CML and important clinical benefit (1) EAST HANOVER, N.J., Dec.
SAN FRANCISCO, Dec.
Additional test for susceptibility in certain types of lymphoma FT. MYERS, Fla., Oct. 23, 2014 /PRNewswire/ -- NeoGenomics, Inc.
High Cost and High Expectations for Clinical Benefits are Major Market Access Hurdles Facing New CML Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., June 2,
FLINT, Mich., May 23, 2014 /PRNewswire-iReach/ -- Diplomat, the nation's largest independent specialty pharmacy, announced that it will be distributing SYNRIBO(®) (omacetaxine mepesuccinate),
- BL-8040 study published in Molecular Cancer Therapeutics - JERUSALEM, Feb.
Research led by St. Jude Children's Research Hospital scientists has linked an inherited gene variation to a nearly four-fold increased risk of developing a pediatric acute lymphoblastic leukemia (ALL) subtype that is associated with a poor outcome.